HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY USING TOTAL BODY IRRADIATION

使用全身照射的高剂量免疫抑制治疗

• 批准号: 7606272
• 负责人: ROBERT SIMMS
• 金额: $ 0.21万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-01-03 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606272
• 关键词: Autoimmune Diseases; Cardiac; Computer Retrieval of Information on Scientific Projects Database; Cyclophosphamide; Diffuse Scleroderma; Disease; Disease-Free Survival; Dose; Funding; Gastrointestinal Diseases; Grant; Institution; Kidney; Lung; Physiologic pulse; Pulse taking; Randomized; Research; Research Personnel; Resources; Secondary to; Source; Stem cell transplant; Systemic Scleroderma; Therapeutic immunosuppression; United States National Institutes of Health; Whole-Body Irradiation; mortality

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Severe systemic sclerosis (SSc) is a serious and disabling autoimmune disorder. Severe forms of the disease, particularly rapidly progressive diffuse SSc, are associated with a significant mortality secondary to pulmonary, cardiac, renal and gastrointestinal disease. Hypothesis: Event free survival will be greater in subjects receiving HDIT followed by stem cell transplantation than in subjects receiving pulse IV cyclophosphamide at 44 months after randomization.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 严重系统性硬化症（SSc）是一种严重的致残性自身免疫性疾病。严重形式的疾病，特别是快速进行性弥漫性SSc，与继发于肺、心脏、肾脏和胃肠道疾病的显著死亡率相关。 假设：随机化后44个月时，接受HDIT后进行干细胞移植的受试者的无事件生存期高于接受环磷酰胺静脉冲击的受试者。